Hepatitis C

Top Story

AbbVie receives CHMP positive opinion for Maviret for chronic HCV

June 23, 2017

AbbVie has received a positive opinion from the Committee for Medicinal Products for Human Use for its ribavirin-free regimen Maviret for the treatment of chronic hepatitis C of all genotypes, according to a press release.

“Maviret represents a new generation of HCV therapy and has the potential to be a shorter, 8-week option for patients living with this serious, chronic illness,” Michael Severino, MD, executive vice president, research and development and chief scientific officer at AbbVie, said in the release. “Today’s CHMP positive opinion takes us closer to delivering on AbbVie’s mission to address continued unmet needs by bringing a new pan-genotypic option to people living with HCV in Europe.”

Gilead Sciences receives CHMP positive opinion for DAA Vosevi

June 23, 2017
Gilead Sciences announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization…
In the Journals

Interferon-based SVR in HCV reduced risk for extrahepatic manifestations

June 23, 2017
Sustained virologic response following interferon-based antiviral therapy in patients with hepatitis C reduced the risk for extrahepatic manifestations, according to…
In the Journals

Early decompensation predicts mortality in successfully treated HCC

June 21, 2017
The most significant risk factor for mortality in patients with hepatitis C-related cirrhosis and successfully treated hepatocellular carcinoma was hepatic…
CME

HCV Updates and Case Challenges for the Rapidly Changing Landscape

This activity is supported by an educational grant from Merck & Co., Inc.

In the past few years, significant progress has been made in the treatment of chronic hepatitis C virus (HCV). Highly…
More »
GI Bookshelf

Chapter 9: Gastroduodenal Stents

From Self-Expanding Stents in Gastrointestinal Endoscopy
More »
Featured
Digestive Disease Week

Digestive Disease Week

Video
Meeting News

VIDEO: Telemedicine aids treatment of patients with HCV, substance use disorders

April 23, 2017
More »

AbbVie receives CHMP positive opinion for Maviret for chronic HCV

June 23, 2017
AbbVie has received a positive opinion from the Committee for Medicinal Products for Human Use for its ribavirin-free regimen Maviret for the…

Gilead Sciences receives CHMP positive opinion for DAA Vosevi

June 23, 2017
Gilead Sciences announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing…

In the Journals

Interferon-based SVR in HCV reduced risk for extrahepatic manifestations

June 23, 2017
Sustained virologic response following interferon-based antiviral therapy in patients with hepatitis C reduced the risk for extrahepatic…

In the Journals

Early decompensation predicts mortality in successfully treated HCC

June 21, 2017
The most significant risk factor for mortality in patients with hepatitis C-related cirrhosis and successfully treated hepatocellular carcinoma was…

In the Journals

MELD score determines DAAs’ cost-effectiveness pre- or post-transplant

June 20, 2017
Direct-acting antiviral treatment in patients with hepatitis C and cirrhosis was most cost-effective and cost-saving pre-liver transplant among those…

In the Journals Plus

Electronic HCV screening intervention improves testing, linkage to care in baby boomers

June 16, 2017
An electronic health record clinical decision support tool significantly increased hepatitis C virus screening, as well as follow-up testing and

Experts release new recommendations for the elimination of HCV in the U.S.

June 16, 2017
A recent report from the O’Neill Institute for National and Global Health Law at Georgetown University provides key recommendations for the…

In the Journals

Urban clinic achieves high SVR rates in HCV/HIV coinfected patients

June 14, 2017
Patients with hepatitis C and HIV coinfection had high rates of sustained virologic response in an urban clinical setting with the use of standard…

Regulus plans to discontinue micro-RNA candidate for HCV

June 13, 2017
Regulus Therapeutics announced its plans to discontinue development of RG-101 for hepatitis C, according to a press release. Additionally, the…

In the Journals

SOF/VEL/VOX with, without RBV effective in DAA-experienced HCV patients

June 12, 2017
Fixed dose treatment with sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin for 12 weeks was effective and well-tolerated in patients…

More Headlines »
Advertisement
Advertisement